Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ \ Origin: Appendix 5 \ \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 1/03/13$ 

ABN		
30 118	3 758 946	
We (	the entity) give ASX the following	g information.
_	t 1 - All issues	h sheets if there is not enough space)
10a m	ast complete the relevant sections (attac	n sheets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Ordinary fully paid shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	3,500,000
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares

Name of entity

KALIA LIMITED

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	\$0.006
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of options (exercise price \$0.006, expiry 13 May 2019)
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	28 November 2017
6с	Number of *securities issued without security holder approval under rule 7.1	n/a

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	n/a	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	n/a	
6f	Number of *securities issued under an exception in rule 7.2	3,500,000	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	n/a	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	n/a	
<i>c</i> ·		D 1	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1 – 213,152,109 Rule 7.1A – 195,434,739	
7	<sup>+</sup> Issue dates	11 January 2018	
7	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	ii jailuai y 2016	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	2,034,347,391	Ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
44,500,000	Unlisted Options
	Exercise Price
	\$0.006 expiry 13
	May 2019
250,000,000	Class A Performance
	Shares
250,000,000	Class B Performance
	Shares
250,000,000	Class C Performance
	Shares
250,000,000	Unlisted Adviser
, , ,	Options Exercise
	Price \$0.003 expiry
	30 June 2019

Dividend policy (in the case of a
trust, distribution policy) on the
increased capital (interests)

n/a			

#### Part 2 - Pro rata issue

11	Is security holder approval N required?	I/A
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their	
	entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
	Names of any underwriters	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
	Eas or sammission navable to	
23	Fee or commission payable to the broker to the issue	
	A	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which	
	notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	

<sup>+</sup> See chapter 19 for defined terms.

You need only complete this section if you are applying for quotation of securi  34 Type of *securities	ries
their entitlements in full through a broker?  31 How do security holders sell part of their entitlements through a broker and accept for the balance?  32 How do security holders dispose of their entitlements (except by sale through a broker)?  33 *Issue date  Part 3 - Quotation of securities  You need only complete this section if you are applying for quotation of securities  Type of *securities	'ies
their entitlements in full through a broker?  31 How do security holders sell part of their entitlements through a broker and accept for the balance?  32 How do security holders dispose of their entitlements (except by sale through a broker)?  33 *Issue date  Part 3 - Quotation of securities  You need only complete this section if you are applying for quotation of securities  Type of *securities	ries
of their entitlements through a broker and accept for the balance?  32 How do security holders dispose of their entitlements (except by sale through a broker)?  33 *Issue date  Part 3 - Quotation of securities  You need only complete this section if you are applying for quotation of securities  Type of *securities	'ies
of their entitlements (except by sale through a broker)?  33 *Issue date  Part 3 - Quotation of securities  You need only complete this section if you are applying for quotation of securities  Type of *securities	'ies
Part 3 - Quotation of securities  You need only complete this section if you are applying for quotation of securi  Type of *securities	'ies
You need only complete this section if you are applying for quotation of securi  34 Type of +securities	'ies
(tick one)	
(a) *Securities described in Part 1	
All other <sup>+</sup> securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entities that have ticked box 34(a) Additional securities forming a new class of securities	
Tick to indicate you are providing the information or documents	
If the *securities are *equity securities, the names of the additional *securities, and the number and percentage held by those holders	_
If the *securities are *equity securities, a distribution *securities setting out the number of holders in the car 1 - 1,000 1,001 - 5,000	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

5,001 - 10,000 10,001 - 100,000 100,001 and over A copy of any trust deed for the additional \*securities 37 Entities that have ticked box 34(b) Number of \*securities for which 38 <sup>+</sup>quotation is sought +Class of +securities for which 39 quotation is sought 40 Do the \*securities rank equally in all respects from the +issue date with an existing +class of quoted \*securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Reason for request for quotation 41 now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another \*security, clearly identify that other \*security)

04/03/2013 Appendix 3B Page 7

Number

+Class

<sup>+</sup> See chapter 19 for defined terms.

42	Number and +class of all +securities quoted on ASX ( <i>including</i> the +securities in clause 38)	

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Ama MacPetosh

Sign here:

Date: 12 January 2018

Company secretary

Print name: Anna MacKintosh

<sup>+</sup> See chapter 19 for defined terms.

== == == ==

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figures capacity is calculated	Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	905,955,825			
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid <sup>+</sup>ordinary securities cancelled during that 12 month period</li> </ul>	Option exercise 5,000,000 (5/4/17) 2,000,000 (1/5/17) 10,000,000 (3/5/17) 10,000,000 (30/11/17) 135,893,374 (approved 21/8/17) 722,891,566 (approved 21/8/17) 39,106,626 (approved 21/8/17) 120,000,000 (approved 21/8/17) 3,500.000 (11/1/18)			
"A"	1,954,347,391			

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	293,152,109
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	80,000,000
<ul> <li>Under an exception in rule 7.2</li> </ul>	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	80,000,000
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	293,152,109
Note: number must be same as shown in Step 2	
Subtract "C"	80,000,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	213,152,109
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
<b>Multiply</b> "A" by 0.10	195,434,739
Step 3: Calculate "E", the amount of 7.1A that has already been used	of placement capacity under rule
Insert number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil
Notes:  • This applies to equity securities – not just ordinary securities	
<ul> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> </ul>	
Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security	
<ul> <li>holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"E"	Nil

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10  Note: number must be same as shown in Step 2	195,434,739
Subtract "E"  Note: number must be same as shown in Step 3	Nil
<i>Total</i> ["A" x 0.10] – "E"	195,434,739  Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.